Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - moxifloxacin hydrochloride monohydrate, quantity: 436.33 mg (equivalent: moxifloxacin, qty mg) - tablet, film coated - excipient ingredients: lactose; povidone; lactose monohydrate; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; iron oxide red; macrogol 400 - moxifloxacin apo (moxifloxacin hydrochloride) tablets are indicated for the treatment of adults with infections caused by susceptible organisms in the conditions:,- acute bacterial sinusitis,- community acquired pneumonia,- acute exacerbations of chronic bronchitis,appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin apo may be initiated, in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.,consideration should be given to available official guidance on the appropriate use of antibacterial agents.

United States - English - NLM (National Library of Medicine)

redpharm drug, inc. - moxifloxacin hydrochloride (unii: c53598599t) (moxifloxacin - unii:u188xyd42p) - moxifloxacin 400 mg - 1.1 community acquired pneumonia moxifloxacin hydrochloride is indicated in adult patients for the treatment of community acquired pneumonia caused by susceptible isolates of streptococcus pneumoniae (including multi-drug resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, moraxella catarrhalis, methicillin-susceptible staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae, or chlamydophila pneumoniae [see clinical studies (14.3)]. mdrsp isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [mic] ≥ 2 mcg/ml), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. 1.2 uncomplicated skin and skin structure infections moxifloxacin hydrochloride is indicated in adult patients for the treatment of uncomplicated skin and skin structure infections caused by susceptible isolates of methicillin-susceptible staphylococcus aureus or streptococcus pyoge

United States - English - NLM (National Library of Medicine)

fresenius kabi norge as - moxifloxacin hydrochloride (unii: c53598599t) (moxifloxacin - unii:u188xyd42p) - moxifloxacin 400 mg in 250 ml - moxifloxacin injection is indicated in adults (18 years of age or older) for the treatment of community acquired pneumonia caused by susceptible isolates of streptococcus pneumoniae (including multi-drug resistant isolates*), haemophilus influenzae, moraxella catarrhalis, methicillin-susceptible staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae, or chlamydophila pneumoniae . * mdrsp, multi-drug resistant streptococcus pneumoniae includes isolates previously known as prsp (penicillin-resistant s. pneumoniae ), and are isolates resistant to two or more of the following antibiotics: penicillin (minimum inhibitory concentrations [mic] ≥ 2 mcg/ml), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole [see  clinical studies (14.2)] . moxifloxacin injection is indicated in adu

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - moxifloxacin hydrochloride (unii: c53598599t) (moxifloxacin - unii:u188xyd42p) - moxifloxacin 400 mg in 250 ml - moxifloxacin injection is indicated in adults (18 years of age or older) for the treatment of community acquired pneumonia caused by susceptible isolates of streptococcus pneumoniae (including multi-drug resistant isolates*), haemophilus influenzae, moraxella catarrhalis, methicillin-susceptible staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae, or chlamydophila pneumoniae . * mdrsp, multi-drug resistant streptococcus pneumoniae includes isolates previously known as prsp (penicillin-resistant s. pneumoniae ), and are isolates resistant to two or more of the following antibiotics: penicillin (minimum inhibitory concentrations [mic] ≥ 2 mcg/ml), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole [see clinical studies (14.2)] . moxifloxacin injection is indicated in adults (18 years of age or older) for the treatment of uncomplicated skin and skin structure infections caused by susceptible isolates of methicillin-susceptible

United States - English - NLM (National Library of Medicine)

avpak - moxifloxacin hydrochloride (unii: c53598599t) (moxifloxacin - unii:u188xyd42p) - moxifloxacin 400 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of moxifloxacin hydrochloride tablets and other antibacterial drugs, moxifloxacin hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. moxifloxacin hydrochloride tablets are indicated for the treatment of adults (≥ 18 years of age) with infections caused by susceptible isolates of the designated microorganisms in the conditions listed below [see dosage and administration (2) and use in specific populations (8.5)] . culture and susceptibility testing  

Malta - English - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - moxifloxacin - film-coated tablet - moxifloxacin 400 mg - antibacterials for systemic use

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - moxifloxacin hydrochloride monohydrate -

Malta - English - Medicines Authority

anfarm hellas s.a. 4 achaias str. & trizinias 14564 kifissia, attiki, greece - moxifloxacin hydrochloride - solution for infusion - moxifloxacin hydrochloride 400/250 mg/ml - antibacterials for systemic use

Canada - English - Health Canada

pharmascience inc - moxifloxacin (moxifloxacin hydrochloride) - tablet - 400mg - moxifloxacin (moxifloxacin hydrochloride) 400mg - quinolones

Canada - English - Health Canada

jamp pharma corporation - moxifloxacin (moxifloxacin hydrochloride) - tablet - 400mg - moxifloxacin (moxifloxacin hydrochloride) 400mg - quinolones